B+
Bull case
25%
Probability
Target price
$0.32
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
ERNA
Ernexa TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.14
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.05
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-01
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Primary-source tone is constructive on ERNA-101 development, but the evidence mix still skews cautious because the most concrete near-term filings are about Nasdaq compliance and balance-sheet durability rather than operating proof points. Coverage is thin, no analyst target set was available, the packet carried no recent trusted-news flow, and the deterministic prior remained neutral with low catalyst density, so this remains a tentative monitoring memo rather than a confirmed bullish setup.
RankAlpha Sentiment Codex - 2026-05-01
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-05-03catalystReverse split execution and Nasdaq listing outcomeHigh impact
Ernexa disclosed a March 18, 2026 Nasdaq bid-price deficiency notice and said it would seek a hearing; the company also warned there is no assurance that a favorable Panel decision will be obtained or that its securities will remain listed on The Nasdaq Capital Market. The April 13, 2026 definitive information statement authorized a 1-for-10 to 1-for-25 reverse split, effective no earlier than 20 calendar days after mailing, to support regaining compliance. At ERNA's size, listing status and reverse-split execution remain the nearest stock-specific swing factors [#8-K-2026-03-20] [#DEF14C-2026-04-13].
2026-08-31eventRunway durability after February financingHigh impact
The 2025 10-K said Ernexa had about $1.9 million of cash at December 31, 2025, used about $7.0 million of operating cash in 2025, received about $9.6 million of net proceeds from the February 10, 2026 offering, and still concluded there was substantial doubt about its ability to continue as a going concern absent additional funding. That leaves capital access, dilution, or partnering as a core gating event before clinical entry [#10-K-2026-03-13].
2026-09-30catalystERNA-101 IND submission and first-in-human start windowHigh impact
Company communications said FDA pre-IND feedback provided a path toward IND submission and a first-in-human ovarian-cancer trial, with tech transfer already underway. Reaching IND clearance and opening the study would be the first material operating de-risking step for the platform, but this remains a preclinical milestone path rather than validated clinical evidence [#PR-2026-01-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-01 • Updated nightlySource: Internal modelMethodology